FACIT appoints Anil Amlani as Executive-in-Residence

Photo of author

By Ted Liu

Fight Against Cancer Innovation Trust (FACIT) has appointed Anil Amlani, CPA, as an Executive-in-Residence (EIR) to guide and support emerging oncology investment and management activities in the Medical Device sector.

Amlani has extensive senior executive experience in Canada and USA in Medical Device sector and in Satellite and Telecommunication Industry. Prior to joining FACIT, Amlani held several executive roles including CEO and CFO (VisualSonics), COO and CFO (MDS Proteomics), and CCO (Fujifilm Sonosite). He has also completed over $500M in financings, as well as significant exits with Cancom/StarChoice to Shaw ($675M), VisualSonics (US $67.9M) to Sonosite, and Sonosite to Fujifilm (US $995M).

“FACIT creates and seeds growth companies with a hands-on approach to cultivate sustainable biotechnology start-ups in Ontario, as we have done successfully in the past with companies like Turnstone Biologics, Fusion Therapeutics, and more recently Propellon Therapeutics,” said David O’Neill, Vice President of Business Development at FACIT. “We welcome Anil to the team and will benefit from his extensive experience in the medical device sector. FACIT and its entrepreneur partners can target this market with confidence.”

“Having worked with successful commercial enterprises in both North America and Asia, I have a good appreciation of the challenges emerging companies face in competing for investment and scaling operations,” said Amlani. “Very few places in the world combine the translational model and commercial expertise as robustly as FACIT and their strategic partner, the Ontario Institute for Cancer Research. I am excited to join the team as I believe this thriving model will positively impact investors in growth companies and most importantly, better care for patients with cancer.”

Amlani obtained his Chartered Accountancy designation in London, England and in Canada.